Search results for "Randomized Controlled Trials as Topic"

showing 10 items of 435 documents

The impact of antiviral treatments on the course of chronic hepatitis C: an evidence-based approach.

2004

Hepatitis C virus chronic infection is currently the most common cause of end-stage liver disease. The benefit of antiviral therapy on liver histology and its impact on the long-term course of the disease has been extensively studied. However, the results are still equivocal and the overall assessment of treatment effect remains difficult to evaluate. Although the conclusions of the last National Institute of Health Consensus Development Conferences on Hepatitis C have recently been published, several important issues still remain unanswered. We review the available data by an evidence-based approach and conclude that: 1) peginterferon alfa is more effective than conventional interferon in …

Oncologymedicine.medical_specialtyCirrhosisCarcinoma HepatocellularHepatitis C virusDiseasemedicine.disease_causeAntiviral AgentsLiver diseasechemistry.chemical_compoundMaintenance therapyPegylated interferonInternal medicineDrug DiscoverymedicineHumansViral hepatitis CRandomized Controlled Trials as TopicPharmacologyEvidence-Based Medicinebusiness.industryRibavirinLiver NeoplasmsHistological benefitHepatitis CHepatitis C Chronicmedicine.diseaseLong-term outcomeTreatment OutcomechemistryCombination treatmentImmunologybusinessPegylated interferonmedicine.drugCurrent pharmaceutical design
researchProduct

Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment.

2010

Oncologymedicine.medical_specialtyColorectal cancerDisease-Free SurvivalAdvanced colorectal cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansNeoplasm MetastasisNeoplasm StagingRandomized Controlled Trials as TopicCetuximabbusiness.industryIncidenceCancerAntibodies MonoclonalHematologymedicine.diseaseChemotherapy regimenOxaliplatinCarcinoembryonic AntigenIrinotecanClinical PracticeEuropeTreatment OutcomeOncologybusinessColorectal Neoplasmsmedicine.drugFollow-Up StudiesAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Cetuximab: clinical results in colorectal cancer

2007

In recent years, the introduction of targeted therapies into clinical practice seems to offer incremental benefits in the treatment of metastatic colorectal cancer (mCRC), mainly when they are employed in combination with optimal chemotherapy and/or radiotherapy. In this paper, we focus on Cetuximab and its role in the treatment of mCRC.

Oncologymedicine.medical_specialtyColorectal cancermedicine.medical_treatmentCetuximabAntineoplastic AgentsAntibodies Monoclonal HumanizedClinical Trials Phase II as TopicInternal medicinemedicineHumansEpidermal growth factor receptorNeoplasm MetastasisRandomized Controlled Trials as TopicChemotherapyCetuximabbiologybusiness.industryAntibodies MonoclonalHematologymedicine.diseaseChemotherapy regimendigestive system diseasesSurgeryRadiation therapyClinical trialClinical PracticeClinical Trials Phase III as TopicOncologybiology.proteinColorectal Neoplasmsbusinessmedicine.drugAnnals of Oncology
researchProduct

Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up.

2010

Oncologymedicine.medical_specialtyColorectal cancermedicine.medical_treatmentColonoscopyPharmacotherapyMeta-Analysis as TopicRisk FactorsInternal medicineEpidemiologyAntineoplastic Combined Chemotherapy ProtocolsmedicineSecondary PreventionHumansSurvival analysisEarly Detection of CancerNeoplasm StagingRandomized Controlled Trials as TopicChemotherapymedicine.diagnostic_testbusiness.industryIncidenceCancerHematologyColonoscopymedicine.diseasePrognosisSurvival AnalysisSurgeryCarcinoembryonic AntigenEuropeTreatment OutcomeOncologyChemotherapy AdjuvantColonic NeoplasmsbusinessAdjuvantFollow-Up StudiesAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multice…

2020

Half of patients newly diagnosed with esophageal squamous cell cancer (ESCC) have metastatic disease (mESCC) and therefore a poor prognosis. Furthermore, half of patients with initial loco-regional disease present disease recurrence after surgery and/or chemoradiation. In mESCC, the recommended first-line treatment combines 5-fluorouracil and cisplatin, although this has not been validated by a phase III trial. Patients with disease progression or recurrence after platinum-based chemotherapy and good performance status probably benefit from second-line chemotherapy. Several molecules have been evaluated in phase I/II trials or retrospective studies (docetaxel, paclitaxel and irinotecan) but…

Oncologymedicine.medical_specialtyEsophageal NeoplasmsPaclitaxel[SDV]Life Sciences [q-bio]medicine.medical_treatmentEsophageal cancerPhases of clinical researchIrinotecan03 medical and health scienceschemistry.chemical_compoundClinical Trials Phase II as Topic0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansMulticenter Studies as TopicComputingMilieux_MISCELLANEOUSRandomized Controlled Trials as Topic030304 developmental biologyCisplatin0303 health sciencesChemotherapyHepatologyPerformance statusbusiness.industryGastroenterologyEsophageal cancermedicine.disease3. Good healthSurvival RateIrinotecanPaclitaxelchemistryDocetaxel030220 oncology & carcinogenesisDisease ProgressionQuality of LifeSquamous cell cancerEsophageal Squamous Cell CarcinomaFluorouracilFranceNeoplasm Recurrence Localbusinessmedicine.drugDigestive and Liver Disease
researchProduct

What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis

2015

Abstract: Background: Randomized phase III trials showed interesting, but conflicting results, regarding the treatment of NSCLC, PS2 population. This meta-analysis aims to review all randomized trials comparing platinum-based doublets and single-agents in NSCLC PS2 patients. Materials and methods: Data from all published randomized trials, comparing efficacy and safety of platinum-based doublets to single agents in untreated NSCLC, PS2 patients, were collected. Pooled ORs were calculated for the 1-year Survival-Rate (ly-SR), Overall Response Rate (ORR), and grade 3-4 (G3-4) hematologic toxicities. Results: Six eligible trials (741 patients) were selected. Pooled analysis showed a significan…

Oncologymedicine.medical_specialtyLung NeoplasmsPhase iii trialsSettore MED/06 - Oncologia Medicamedicine.medical_treatmentPopulationSettore MED/21 - Chirurgia ToracicaNSCLClaw.inventionSingle agentOverall response rateRandomized controlled trialPerformance statuNSCLC; Chemotherapy; Performance status; Platinum; Doublet; Single agentlawCarcinoma Non-Small-Cell LungInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansChemotherapyIntensive care medicineeducationRandomized Controlled Trials as TopicPlatinumChemotherapyeducation.field_of_studyPerformance statusbusiness.industryHematologySurvival RateOncologyMeta-analysisDoubletNon small cellHuman medicinePerformance statusbusiness
researchProduct

Current questions for the treatment of advanced gastric cancer.

2013

Abstract Background Gastric cancer remains a major health problem worldwide. Treatment of advanced gastric cancer is controversial and there is no standard regimen for first- or second-line chemotherapy (CT). This review aims to give an overview of the hot topics concerning treatment, prognostic factors and new strategies in advanced gastric cancer. Material and methods Seven questions of special clinical interest have been formulated previously to the literature review. With the aim of answering each of these questions, a specific search of the relevant trials and meta-analyses published or communicated from 1990 to date was performed. Results Patients treated with CT have a survival benef…

Oncologymedicine.medical_specialtymedicine.medical_treatmentAntibodies Monoclonal HumanizedTargeted therapyTrastuzumabStomach NeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansRadiology Nuclear Medicine and imagingMolecular Targeted TherapyRandomized Controlled Trials as TopicPerformance statusbusiness.industryCancerGeneral MedicineTrastuzumabmedicine.diseaseSurgeryOxaliplatinIrinotecanRegimenOncologyDocetaxelbusinessmedicine.drugCancer treatment reviews
researchProduct

INTERVENTIONS TO PREVENT SPORTS RELATED INJURIES: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS

2013

The effects of methods to prevent injuries have been studied in several systematic reviews. However, no meta-analysis taking into account all randomised controlled intervention trials aiming at the prevention of sports injuries has been published.To summarise the effects of sports injury prevention interventions.Systematic review and meta-analysis of randomised controlled trials.PubMed, MEDLINE, SPORTDiscus, the Cochrane Central Register of Controlled Trials, CINAHL, PEDro, and Web of Science, searched in September 2013. The reference lists of retrieved articles and reviews were hand searched.To be selected articles had to examine the effects of any preventive intervention on sports injurie…

Orthotic Devicesmedicine.medical_specialtySports medicineWarm-Up ExercisePsychological interventionPoison controlPhysical Therapy Sports Therapy and RehabilitationSuicide preventionOccupational safety and healthlaw.inventionSports EquipmentRandomized controlled triallawRisk FactorsInjury preventionmedicineHumansOrthopedics and Sports MedicineRandomized Controlled Trials as TopicPhysical Education and Trainingbusiness.industryProtective DevicesHuman factors and ergonomicsGeneral MedicineOrthotic deviceShoesSystematic reviewMeta-analysisAthletic InjuriesPhysical therapyJointsbusinessBritish Journal of Sports Medicine
researchProduct

Endoscopic surveillance in ulcerative colitis: smart biopsies do it better.

2007

Patients with ulcerative colitis (UC) have a significantly higher risk for the development of colitisassociated colorectal cancer. Endoscopic surveillance is recommended. The growth pattern of dysplastic tissue is often multifocal and flat. Thus, significant lesions might be overlooked. Multiple random biopsies are recommended, but cannot eliminate the possibility of missed cancers with severe consequences for the patient. Chromoendoscopy with methylene blue or indigo carmine can unmask flat lesions and may solve this problem. In addition, confocal laser endomicroscopy enables in vivo histology with subcellular resolution during ongoing colonoscopy and leads to highly selected mucosal biops…

Pathologymedicine.medical_specialtyBiopsyColonoscopyStainSensitivity and SpecificityEndoscopy GastrointestinalChromoendoscopychemistry.chemical_compoundMedicineHumansRandomized Controlled Trials as TopicHepatologymedicine.diagnostic_testStaining and Labelingbusiness.industryGastroenterologyHistologyColonoscopymedicine.diseaseUlcerative colitisStainingIndigo carminechemistryDysplasiaColitis UlcerativebusinessColorectal NeoplasmsGastroenterology
researchProduct

Erythropoietin and subarachnoid hemorrhage.

2010

Pathologymedicine.medical_specialtySubarachnoid hemorrhageErytTime Factorserythropoietin subarachnoid hemorragelaw.inventionAnimals; Brain Ischemia; Clinical Trials; Phase II as Topic; Disease Models; Animal; Eryt; Humans; Neuroprotective Agents; Randomized Controlled Trials as Topic; Recombinant Proteins; Subarachnoid Hemorrhage; Time Factors; hropoietinBrain IschemiaBrain ischemialawmedicineAnimalsHumansClinical TrialsRandomized Controlled Trials as TopicSettore MED/27 - Neurochirurgiabusiness.industryAnimalPhase II as TopicGeneral MedicinehropoietinSubarachnoid Hemorrhagemedicine.diseaseRecombinant ProteinsNeuroprotective AgentsErythropoietinDisease ModelsRecombinant DNAbusinessmedicine.drug
researchProduct